Search

Your search keyword '"Chapman, M John"' showing total 924 results
Start Over Author "Chapman, M John"
924 results on '"Chapman, M John"'

55. The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

Author

Fruchart, Jean-Charles, Sacks, Frank, Hermans, Michel P., Assmann, Gerd, Brown, W. Virgil, Ceska, Richard, Chapman, M. John, Dodson, Paul M., Fioretto, Paola, Ginsberg, Henry N., Kadowaki, Takashi, Lablanche, Jean-Marc, Marx, Nikolaus, Plutzky, Jorge, Reiner, Željko, Rosenson, Robert S., Staels, Bart, Stock, Jane K., Sy, Rody, Wanner, Christoph, Zambon, Alberto, and Zimmet, Paul

Published
2008
Full Text
View/download PDF

58. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Author

Mach, Francois, Baigent, Colin, Catapano, Alberico L., Koskinas, Konstantinos C., Casula, Manuela, Badimon, Lina, Chapman, M. John, De Backer, Guy G., Delgado, Victoria, Ference, Brian A., Graham, Ian M., Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R., Riccardi, Gabriele, Richter, Dimitrios J., Sabatine, Marc S., Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Nibouche, Djamaleddine, Zelveian, Parounak H., Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Viigimaa, Margus, Strandberg, Timo E., Ferrieres, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, Laszlo, Gudjonsson, Thorbjorn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstol, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, Perez de Isla, Leopoldo, Hagstrom, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S., Windecker, Stephan, Aboyans, Victor, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Juni, Peter, Katus, Hugo A., Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Petronio, Anna Sonia, Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, and Touyz, Rhian M.

Published
2020
Full Text
View/download PDF

59. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Author

Mach, Francois, Baigent, Colin, Catapano, Alberico L., Koskinas, Konstantinos C., Casula, Manuela, Badimon, Lina, Chapman, M. John, De Backer, Guy G., Delgado, Victoria, Ference, Brian A., Graham, Ian M., Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R., Riccardi, Gabriele, Richter, Dimitrios J., Sabatine, Marc S., Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Nibouche, Djamaleddine, Zelveian, Parounak H., Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Viigimaa, Margus, Strandberg, Timo E., Ferrieres, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, Laszlo, Gudjonsson, Thorbjorn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstol, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagstrom, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S., Windecker, Stephan, Aboyans, Victor, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Juni, Peter, Katus, Hugo A., Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Petronio, Anna Sonia, Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, and Touyz, Rhian M.

Published
2020
Full Text
View/download PDF

61. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society

Author

Nordestgaard, Børge G., Chapman, M. John, Humphries, Steve E., Ginsberg, Henry N., Masana, Luis, Descamps, Olivier S., Wiklund, Olov, Hegele, Robert A., Raal, Frederick J., Defesche, Joep C., Wiegman, Albert, Santos, Raul D., Watts, Gerald F., Parhofer, Klaus G., Hovingh, G. Kees, Kovanen, Petri T., Boileau, Catherine, Averna, Maurizio, Borén, Jan, Bruckert, Eric, Catapano, Alberico L., Kuivenhoven, Jan Albert, Pajukanta, Päivi, Ray, Kausik, Stalenhoef, Anton F. H., Stroes, Erik, Taskinen, Marja-Riitta, and Tybjærg-Hansen, Anne

Published
2013
Full Text
View/download PDF

63. Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias: JACC State-of-the-Art Review

Author

Katzmann, Julius, Packard, Chris, Chapman, M. John, Katzmann, Isabell, Laufs, Ulrich, University Hospital Leipzig, University of Glasgow, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM), Zeisigwaldkliniken Bethanie Chemnits, Gestionnaire, HAL Sorbonne Université 5, Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
PCSK9, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, angiopoietin-like 3? apolipoprotein CIII? ASO? lipoprotein(a), siRNA, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract

International audience; There is an unmet clinical need to reduce residual cardiovascular risk attributable to apolipoprotein B-containing lipoproteins, particularly low-density lipoprotein and remnant particles. Pharmacological targeting of messenger RNA represents an emerging, innovative approach. Two major classes of agents have been developed—antisense oligonucleotides and small interfering RNA. Early problems with their use have been overcome by conjugation with N-acetylgalactosamine, an adduct that targets their delivery to the primary site of action in the liver. Using these agents to inhibit the translation of key regulatory proteins such as PCSK9, apolipoprotein CIII, apolipoprotein(a), and angiopoietin-like 3 has been shown to be effective in attenuating dyslipidemic states. Cardiovascular outcome trials with N-acetylgalactosamine–conjugated RNA-targeting drugs are ongoing. The advantages of these agents include long dosing intervals of up to 6 months and the potential to regulate the abundance of any disease-related protein. Long-term safety has yet to be demonstrated in large-scale clinical trials.

Published
2020

64. Low-density lipoproteins cause atherosclerotic cardiovascular disease:\ud pathophysiological, genetic and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Author

Boren, Jan, Chapman, M. John, Krauss, Ronald M., Packard, Chris J., Bentzon, Jacob, Binder, Christoph J., Daeman, Mat J., Demer, Linda L., Hegele, Robert A., Nicholls, Stephen J., Nordestgaard, Borge G., Watts, Gerald F., Bruckert, Eric, Fazio, Sergio, Ference, Brian A., Graham, Ian, Horton, Jay D., Landmesser, Ulf, Laufs, Ulrich, Masana, Luis, Pasterkamp, Gerard, Raal, Frederick J., Ray, Kausik K., Schunkert, Heribert, Taskinen, Marja-Ritta, van de Sluis, Bart, Wiklund, Olov, Tokogozoglu, Lale, Catapano, Alberico L., and Ginsberg, Henry N.

Subjects
ComputingMethodologies_COMPUTERGRAPHICS
Abstract

Graphic abstract available.

Published
2020

66. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Author

Nordestgaard, Børge G, Langlois, Michel R, Langsted, Anne, Chapman, M John, Aakre, Kristin M, Baum, Hannsjörg, Borén, Jan, Bruckert, Eric, Catapano, Alberico, Cobbaert, Christa, Collinson, Paul, Descamps, Olivier S, Duff, Christopher J, von Eckardstein, Arnold, Hammerer-Lercher, Angelika, Kamstrup, Pia R, Kolovou, Genovefa, Kronenberg, Florian, Mora, Samia, Pulkki, Kari, Remaley, Alan T, Rifai, Nader, Ros, Emilio, Stankovic, Sanja, Stavljenic-Rukavina, Ana, Sypniewska, Grazyna, Watts, Gerald F, Wiklund, Olov, Laitinen, Päivi, European Atherosclerosis Society (EAS) and the European Federati, University of Zurich, and Nordestgaard, Børge G

Subjects
540 Chemistry, 610 Medicine & health, lipids (amino acids, peptides, and proteins), 2705 Cardiology and Cardiovascular Medicine, 10038 Institute of Clinical Chemistry
Abstract

The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), LDL cholesterol (LDLC), and calculated non-HDLC (=total - HDLC) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDLC is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDLC shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a) [Lp(a)]-cholesterol is part of measured or calculated LDLC and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDLC declines poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDLC or apolipoprotein B (apoB), especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDLC includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apoB measurement can detect elevated LDL particle (LDLP) numbers often unidentified on the basis of LDLC alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.

Published
2020

67. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Author

Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A, Graham, Ian M, Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R, Riccardi, Gabriele, Richter, Dimitrios J, Sabatine, Marc S, Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Mueller, Christian, Drexel, Heinz, Aboyans, Victor, Corsini, Alberto, Doehner, Wolfram, Farnier, Michel, Gigante, Bruna, Kayikcioglu, Meral, Krstacic, Goran, Lambrinou, Ekaterini, Lewis, Basil S, Masip, Josep, Moulin, Philippe, Petersen, Steffen, Petronio, Anna Sonia, Piepoli, Massimo Francesco, Pintó, Xavier, Räber, Lorenz, Ray, Kausik K, Reiner, Željko, Riesen, Walter F, Roffi, Marco, Schmid, Jean- Paul, Shlyakhto, Evgeny, Simpson, Iain A, Stroes, Erik, Sudano, Isabella, Tselepis, Alexandros D, Viigimaa, Margus, Vindis, Cecile, Vonbank, Alexander, Vrablik, Michal, Vrsalovic, Mislav, Zamorano, José Luis, Collet, Jean- Philippe, John Chapman, M, Windecker, Stephan, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A, Leclercq, Christophe, Lettino, Maddalena, Merkely, Bela, Sousa-Uva, Miguel, Touyz, Rhian M, Nibouche, Djamaleddine, Zelveian, Parounak H, Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Strandberg, Timo E, Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S, ESC Scientific Document Group, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Zurich, and Mach, François

Subjects
medicine.medical_specialty, Treatment adherence, Evinacumab, [SDV]Life Sciences [q-bio], Very low-density lipoproteins, 610 Medicine & health, Lipoprotein remnants, 030204 cardiovascular system & hematology, Guidelines, Total cardiovascular risk, 2705 Cardiology and Cardiovascular Medicine, Treatment (lifestyle), 03 medical and health sciences, 0302 clinical medicine, Risk Factors, medicine, Humans, 030212 general & internal medicine, High-density lipoproteins, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, Dyslipidaemias, Triglycerides, Dyslipidemias, Task force, business.industry, Treatment (drugs), Lipids, Coronary heart disease, 3. Good health, Treatment (adherence), Cholesterol, Cardiovascular Diseases, Heart Disease Risk Factors, 10209 Clinic for Cardiology, European atherosclerosis society, LDL Cholesterol Lipoproteins, Low-density lipoproteins, Lipid modification, Cardiology and Cardiovascular Medicine, business, Familial hypercholesterolaemia, Apolipoprotein B, All cause mortality, Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia, Lipoprotein(a)
Abstract

The previous ESC/EAS lipid Guidelines were published in August 2016. The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines. New evidence has confirmed that the key initiating event in atherogenesis is the retention of low- density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B containing lipoproteins within the arterial wall. Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect.

Published
2020
Full Text
View/download PDF

72. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues

Author

Huby, Thierry, Doucet, Chantal, Dachet, Christiane, Ouzilleau, Betty, Ueda, Yukihiko, Afzal, Veena, Rubin, Edward, Chapman, M. John, and Lesnik, Philippe

Subjects
Mice -- Research, Liver diseases -- Research, Medical research, Medicine, Experimental
Abstract

Scavenger receptor SR-BI has been implicated in HDL-dependent atheroprotective mechanisms. We report the generation of an SR-BI conditional knockout mouse model in which SR-BI gene targeting by loxP site insertion [...]

Published
2006

79. Apolipoprotein A-II/A-I ratio is a key determinant in vivo of HDL concentration and formation of pre-beta HDL containing apolipoprotein A-II

Author

Pastier, Daniele, Dugue, Sonia, Boisfer, Elisabeth, Atger, Veronique, Nhuan Quang Tran, Tol, Arie van, Chapman, M. John, Chambaz, Jean, Laplaud, P. Michel, and Kalopissis, Athina-Despina

Subjects
Biochemistry -- Research, Apolipoproteins -- Analysis, High density lipoproteins -- Analysis, Metabolism -- Analysis, Biological sciences, Chemistry
Abstract

Research has been conducted on the human apolipoprotein A-II expression in mice. The lipoprotein metabolism has been compared in different transgenic lines that display plasma concentrations of human apo A-II and the results are presented.

Published
2001

81. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Author

Reiner, Željko, Catapano, Alberico L., De Backer, Guy, Graham, Ian, Taskinen, Marja-Riitta, Wiklund, Olov, Agewall, Stefan, Alegria, Eduardo, Chapman, M. John, Durrington, Paul, Erdine, Serap, Halcox, Julian, Hobbs, Richard, Kjekshus, John, Filardi, Pasquale Perrone, Riccardi, Gabriele, Storey, Robert F., Wood, David, Bax, Jeroen, Vahanian, Alec, Auricchio, Angelo, Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Filippatos, Gerasimos, Funck-Brentano, Christian, Hasdai, David, Hobbs, Richard, Hoes, Arno, Kearney, Peter, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Poldermans, Don, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vardas, Panos, Widimsky, Petr, Windecker, Stephan, Reviewers:, Document, Funck-Brentano, Christian, Poldermans, Don, Berkenboom, Guy, De Graaf, Jacqueline, Descamps, Olivier, Gotcheva, Nina, Griffith, Kathryn, Guida, Guido Francesco, Gulec, Sadi, Henkin, Yaakov, Huber, Kurt, Kesaniemi, Y. Antero, Lekakis, John, Manolis, Athanasios J., Marques-Vidal, Pedro, Masana, Luis, McMurray, John, Mendes, Miguel, Pagava, Zurab, Pedersen, Terje, Prescott, Eva, Rato, Quitéria, Rosano, Giuseppe, Sans, Susana, Stalenhoef, Anton, Tokgozoglu, Lale, Viigimaa, Margus, Wittekoek, M. E., and Zamorano, Jose Luis

Published
2011
Full Text
View/download PDF

82. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

Author

Chapman, M. John, Ginsberg, Henry N., Amarenco, Pierre, Andreotti, Felicita, Borén, Jan, Catapano, Alberico L., Descamps, Olivier S., Fisher, Edward, Kovanen, Petri T., Kuivenhoven, Jan Albert, Lesnik, Philippe, Masana, Luis, Nordestgaard, Børge G., Ray, Kausik K., Reiner, Zeljko, Taskinen, Marja-Riitta, Tokgözoglu, Lale, Tybjærg-Hansen, Anne, and Watts, Gerald F.

Published
2011
Full Text
View/download PDF

85. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

Author

Gallo, Antonio, primary, Charriere, Sybil, additional, Vimont, Alexandre, additional, Chapman, M. John, additional, Angoulvant, Denis, additional, Boccara, Franck, additional, Cariou, Bertrand, additional, Carreau, Valérie, additional, Carrié, Alain, additional, Bruckert, Eric, additional, Béliard, Sophie, additional, Beliard, Sophie, additional, Carrie, Alain, additional, Cottin, Yves, additional, Filippo, Mathilde DI., additional, Dulong, Sonia, additional, Durlach, Vincent, additional, Farnier, Michel, additional, Ferrari, Emile, additional, Ferrieres, Dorota, additional, Ferrieres, Jean, additional, Gallo, Antonio, additional, Giral, Philippe, additional, Gonbert, Sophie, additional, Hankard, Regis, additional, Inamo, Jocelyn, additional, Kalmykova, Olga, additional, Krempf, Michel, additional, Moulin, Philippe, additional, Paillard, François, additional, Peretti, Noel, additional, Perrin, Agnes, additional, Pierre Rabes, Jean, additional, Sultan, Ariane, additional, Tounian, Patrick, additional, Valero, René, additional, Verges, Bruno, additional, Yelnik, Cecile, additional, and Ziegler, Olivier, additional

Published
2020
Full Text
View/download PDF

87. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk

Author

Mach, Francois, primary, Baigent, Colin, additional, Catapano, Alberico L., additional, Koskinas, Konstantinos C., additional, Casula, Manuela, additional, Badimon, Lina, additional, Chapman, M. John, additional, De Backer, Guy G., additional, Delgado, Victoria, additional, Ference, Brian A., additional, Graham, Ian M., additional, Halliday, Alison, additional, Landmesser, Ulf, additional, Mihaylova, Borislava, additional, Pedersen, Terje R., additional, Riccardi, Gabriele, additional, Richter, Dimitrios J., additional, Sabatine, Marc S., additional, Taskinen, Marja-Riitta, additional, Tokgozoglu, Lale, additional, and Wiklund, Olov, additional

Published
2020
Full Text
View/download PDF

89. Lipoprotein(a) as a cardiovascular risk factor: current status

Author

Nordestgaard, Børge G., Chapman, M. John, Ray, Kausik, Borén, Jan, Andreotti, Felicita, Watts, Gerald F., Ginsberg, Henry, Amarenco, Pierre, Catapano, Alberico, Descamps, Olivier S., Fisher, Edward, Kovanen, Petri T., Kuivenhoven, Jan Albert, Lesnik, Philippe, Masana, Luis, Reiner, Zeljko, Taskinen, Marja-Riitta, Tokgözoglu, Lale, and Tybjærg-Hansen, Anne

Published
2010
Full Text
View/download PDF

92. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Author

Langlois, Michel R., primary, Nordestgaard, Børge G., additional, Langsted, Anne, additional, Chapman, M. John, additional, Aakre, Kristin M., additional, Baum, Hannsjörg, additional, Borén, Jan, additional, Bruckert, Eric, additional, Catapano, Alberico, additional, Cobbaert, Christa, additional, Collinson, Paul, additional, Descamps, Olivier S., additional, Duff, Christopher J., additional, von Eckardstein, Arnold, additional, Hammerer-Lercher, Angelika, additional, Kamstrup, Pia R., additional, Kolovou, Genovefa, additional, Kronenberg, Florian, additional, Mora, Samia, additional, Pulkki, Kari, additional, Remaley, Alan T., additional, Rifai, Nader, additional, Ros, Emilio, additional, Stankovic, Sanja, additional, Stavljenic-Rukavina, Ana, additional, Sypniewska, Grazyna, additional, Watts, Gerald F., additional, Wiklund, Olov, additional, and Laitinen, Päivi, additional

Published
2019
Full Text
View/download PDF

98. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction

Author

Lund-Katz, Sissel, Laplaud, P. Michel, Phillips, Michael C., and Chapman, M. John

Subjects
Low density lipoproteins -- Research, Coronary heart disease -- Research, Apolipoproteins -- Research, Biological sciences, Chemistry
Abstract

A study was conducted to examine the plasma low-density lipoprotein (LDL) profile in patients with coronary artery disease using a predominance of small, dense LDL. LDL was obtained from fresh plasma of normolipedimic donors using ultracentrifugation. Results indicated that intermediate LDL subspecies correlated with the optimal ligand for the LDL receptor among LDL particle subpopulations.

Published
1998

99. Thermal stability of apolipoprotein B100 in low-density lipoprotein is disrupted at early stages of oxidation while neutral lipid core organization is conserved

Author

Prassl, Ruth, Schuster, Bernhard, Laggner, Peter, Flamant, Claudie, Nigon, Fabienne, and Chapman, M. John

Subjects
Apolipoproteins -- Analysis, Low density lipoproteins -- Research, Oxidation-reduction reaction -- Research, Protein folding -- Research, Biological sciences, Chemistry
Abstract

A study was conducted on the time course of the unfolding characteristics of the protein moiety and of the thermotropic behavior of the core-located apolar lipids of low-density lipoprotein subspecies. The findings indicate that even minimal oxidative modification of apo-B100 has a significant influence on the stability of the monomeric protein. On the other hand, the core lipids maintained features of an ordered arrangement even during propagation of lipid peroxidation.

Published
1998

100. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel

Author

BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. CASTRO, CHAPMAN, M. JOHN, COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., FURBERG, C. D., GAGNE, C., HAFFNER, S. M., HUMPHRIES, S. E., JUNGNER, I., KRAUSS, R. M., KWITEROVICH, P., MARCOVINA, S., PACKARD, C. J., PEARSON, T. A., REDDY, K. SRINATH, ROSENSON, R., SARRAFZADEGAN, N., SNIDERMAN, A. D., STALENHOEF, A. F., STEIN, E., TALMUD, P. J., TONKIN, A. M., WALLDIUS, G., and WILLIAMS, K. M. S.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results